Topline
Moderna’s stock soared by 85% in early trading on Wednesday, nearly doubling the biotech giant’s share price after the firm announced positive results from its first-ever late-stage trial of an experimental cancer vaccine.
The trial marked the first successful final-stage study for any mRNA-based cancer therapy.
Getty Images
Key Facts
Shares of Moderna soared by 85% in premarket trading on Wednesday, pacing what would be the stock’s best-ever trading session after surging by more than 100% earlier in the morning.
This is a developing story.
Leave a comment